OUR STORY

Our CEO Peter Buhl Jensen tells the MPI story.

OUR CORE TEAM

PETER BUHL JENSEN
PETER BUHL JENSEN
CHIEF EXECUTIVE OFFICER Management team
Dr. Buhl Jensen is MD, DMSc and professor in clinical oncology and former lead oncologist –cofounder and CEO at Topotarget A/S.
STEEN KNUDSEN
STEEN KNUDSEN
CHIEF SCIENCE OFFICER FOUNDER management team
Steen is the founder of Medical Prognosis Institute and the inventor of DRP™. The Drug Response Prediction Platform is MPI’s core technology and science platform.
NIELS LAURSEN
NIELS LAURSEN
CHIEF FINANCIAL OFFICER Management team
Niels Laursen has extensive experience within public Danish and international biotech. This has given him a broad knowledge within operations and financial issues.
ULLA HALD BUHL
ULLA HALD BUHL
CHIEF IR & COMMUNICATIONS OFFICER CHIEF CLINICAL OPERATIONS management team
Ulla is our Chief Investor Relations & Communications Officer. She has a wide experience developing anticancer drugs, clinical trials, organizational management and communications.
THOMAS JENSEN
THOMAS JENSEN
CHIEF TECHNOLOGY OFFICER & INVESTOR RELATIONS
Thomas is a pioneer in bridging good science, effective laboratory techniques and bioinformatics to advance the biology of cancer.
ANNIE RASMUSSEN
ANNIE RASMUSSEN
CLINICAL OPERATIONS
Annie has extensive experience in clinical oncology 1982 -1991 and oncology clinical trials 1991-1997 in organization, management, education and leadership
CLAUS DEICHGRÆBER
CLAUS DEICHGRÆBER
VP, EUROPEAN SALES
Claus’ focus is informing about our DRP™ platform, and building MPI´s presence in the European market. He foster relationships and create opportunities to help innovate within the oncology field.
IDA T. HAAKANSSON
IDA T. HAAKANSSON
LABORATORY TECHNICIAN
Ida is MPI's key laboratory technician with resilient dedication to science research to help achieve MPI's laboratory objectives.
RODOLFO DE LÉON
RODOLFO DE LÉON
CHIEF DESIGN OFFICER
I lead to advance Personalised Medicine by leveraging Design as an executive business tool to help MPI's business thrive. To take to the market our game changing approach to innovate cancer care and help cure cancer.
ANKER HANSEN
ANKER HANSEN
HEAD OF LABORATORY / QUALITY DIRECTOR
Anker leads MPI's microarray laboratories and daily routines. He insures the quality and fluid operations in our laboratories.
JAMES G. CULLEM, J.D.
JAMES G. CULLEM, J.D.
VP, Corporate Development
James is a career life sciences entrepreneur and executive who brings 20+ years of diverse experience in the creation, management, and growth of early-stage companies.

 

"We believe that the best way to effective cancer treatments is to empower the medical innovators with the best technology tools combined with cutting edge science.

 

OUR BOARD OF DIRECTORS

FRANK KNUDSEN
CHAIRMAN OF THE BOARD
Director of Finance and Administration, Glycom A/S.
Read more
PETER BUHL JENSEN
CHIEF EXECUTIVE OFFICER at MPI
Dr. Buhl Jensen is MD, DMSc and professor in clinical oncology.
Read more
STEEN KNUDSEN
FOUNDER & CHIEF SCIENCE OFFICER AT MPI
Steen is the founder of Medical Prognosis Institute and the inventor of DRP™. The Drug Response Prediction Platform is MPI’s core technology and science platform.
Read more
NIELS JOHANSEN
Sr. Director, Vaccine Research & Discovery at ALK Abelló
MAGNUS PERSSON
CEO at Karolinska Institutet Holding AB
Dr Persson brings 20 years of international experience from leadership in Life Science innovation, development and financing. He has been a Partner in two Life Sciences Venture Capital firms, one with its base in Sweden and with global reach and one in Th
Read more

OUR BUSINESS AREAS

 

DRP™ PLATFORM
MPI’s business and value creation are founded around our core technology & science methodology platform – DRP™ PLATFORM. The tool for rational drug development and personalized medicine.


ventures
is our business unit where we focus on business development ventures. Our strategic formula here is the fusion of precision business acumen & the efficacy of the DRP™ PLATFORM output. A company operating within this business arm is Oncology Venture with the key mission to position oncology drugs with precision.


+ labs
is our discovery business unit where we invent, prototype & prove relevant new techniques, scientific methodologies and business models. These concepts are curated and honed with the intention to grow the core MPI business areas. It is our playground where we facilitate for the magical collusion of big data, good science and design thinking.


predict
is our current core business to business unit where we utilize the DRP™ PLATFORM to generate drug response prediction reports & patient response prediction reports for our customers. Orchestrating the contextual relationship between the patient, physicians and payers is an important touch point we focus within this business unit.


personal
is our business unit where we innovate within personalized medicine with focus on developing business to consumer products and services that inform, curate & formulate personalized treatments with the best efficacy.


lung chip
 is our business unit where we operate our Lung Chip diagnostics.